Researcher
Benedicte De Winter
- Research Expertise:- Visceral pain - Inflammation - ileus - irritable bowel syndrome - IBS - inflammatory bowel disease - IBD - sepsis - experimental and clinical translational research - medisch vaardighedenonderwijs
- Keywords:VISCERAL PAIN, SEPSIS, IRRITABLE BOWEL SYNDROME, INFLAMMATION, INFLAMMATORY BOWEL DISEASE, Medicine
- Disciplines:Gastro-enterology, Inflammation, Pathophysiology
- Research techniques:- in vivo animal models of IBS, IBD and sepsis - visceromotor response and afferent neuronal activity - motility and sensitivity assays - inflammation measurements - Elisa, flowcytometry - vaardigheden, portfolio, stationsproeven
- Users of research expertise:- research labs - pharmaceutical industry - (bio-, para-) medical schools
Affiliations
- Laboratory Experimental Medicine and Pediatrics (LEMP) (Research group)
Responsible
From1 Oct 2013 → Today - Laboratory Experimental Medicine and Pediatrics (LEMP) (Research group)
Member
From1 Oct 2003 → 30 Sep 2013 - Primary and interdisciplinary care Antwerp (ELIZA) (Research group)
Member
From1 Oct 2003 → 30 Sep 2008
Projects
1 - 10 of 32
- Automation of a mucin mRNA isoform-based biomarker platform to monitor patients with inflammatory bowel diseases.From1 Apr 2024 → TodayFunding: IOF - technology validation in lab
- Crosstalk between MUC13 signalling and the mucosal microbiota in gastric cancer development.From1 Jan 2024 → TodayFunding: Nonprofit institution or equivalents
- REspiratory Virus Repository ANTwerp (ReViRAnt).From1 Jan 2023 → TodayFunding: Flemish Resilience. Government of Flanders Recovery Plan - strengthening R&D
- Turning the understanding of inflammation-related pathology into new biomarkers and treatments using next-generation technologies and high-throughput data mining.From1 Nov 2022 → TodayFunding: BOF - postdoctoral mandates
- A mucin mRNA isoform-based biomarker assay to improve treatment response in patients with inflammatory bowel diseases.From1 Sep 2022 → 31 Aug 2023Funding: IOF - technology validation in lab
- High-end comprehensive GCxGC-QTOF-MS research facility for volatile and semivolatile compounds (GALILEO).From1 Jun 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Assessing health effects of air pollution by non-invasive exhaled breath analysis (ALERT).From1 Jun 2021 → 31 May 2023Funding: Provinces
- Mucin isoform-microbiome crosstalk shaping the course of COVID-19: a help in patient stratification?From1 Nov 2020 → 31 Oct 2021Funding: FWO Special Call for Covid-19 research projects, BOF - projects
- Study of the mechanisms involved in MUC1/MUC13-induced intestinal barrier disruption during inflammatory bowel diseases: a translational approach.From1 Nov 2020 → TodayFunding: FWO junior postdoctoral fellowship
- Functional characterization of human mast cells and basophils in the pathophysiology of diarrhea-predominant irritable bowel syndrome.From1 Oct 2020 → 30 Sep 2022Funding: FWO fellowships
Publications
21 - 30 of 165
- mRNA-1273 vaccine (Moderna)(2022)
Authors: Steven Abrams, Fabienne Mestrez, Benedicte De Winter, Pierre Van Damme, Lissa Pipeleers, Karl Martin Wissing, Kristien Ledeganck
Pages: 799 - 803 - Does peer teaching improve academic results and competencies during medical school? A mixed methods study(2022)
Authors: Marijke Avonts, Nele Michels, Katrien Bombeke, Olivier Vanderveken, Benedicte De Winter
Pages: 1 - 8 - The predictive value of adipokines and metabolic risk factors for dropouts and treatment outcomes in children with obesity treated in a pediatric rehabilitation center(2022)
Authors: Eline Vermeiren, Marijke Ysebaert, Sanae Makhout, Ann De Guchtenaere, Maria Van Helvoirt, Ann Tanghe, Tiffany Naets, Leentje Vervoort, Caroline Braet, Luc Bruyndonckx, et al.
Pages: 1 - 12 - Trends of glucose, lactate and ketones during anaerobic and aerobic exercise in subjects with type 1 diabetes(2022)
Authors: Kristien Ledeganck, Benedicte De Winter, Rie Braspenning, Danaë Delbeke, Eric Renard, Paolo Pozzilli, Silvia Pieralice, Dirk Vissers, Christophe De Block
Pages: 1 - 11 - How the microbiome reshapes obesity research(2022)
Authors: Philip Plaeke, E. Rubens, Benedicte De Winter, Guy Hubens
Pages: 1 - 15 - Volatile organic compound profiling as a potential biomarker in irritable bowel syndrome(2022)
Authors: Kathleen Van Malderen, Nikita Hanning, Helen Lambrechts, Tine Haverhals, Silke Van Marcke, Hannah Ceuleers, Joris De Man, Benedicte De Winter, Kevin Lamote, Heiko De Schepper
Pages: 1 - 12 - Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD(2022)
Authors: Denise van der Graaff, Shivani Chotkoe, Benedicte De Winter, Joris De Man, Christophe Casteleyn, Jean-Pierre Timmermans, Isabel Pintelon, Luisa Vonghia, Wilhelmus Kwanten, Sven Francque
- The role of mucins in gastrointestinal barrier function during health and disease(2022)
Authors: Tom Breugelmans, Baptiste Oosterlinck, Wout Arras, Hannah Ceuleers, Joris De Man, Georgina L Hold, Benedicte De Winter, Annemieke Smet
Pages: 455 - 471 - The role of brain-derived neurotrophic factor in obstructive sleep apnea and endothelial function in a pediatric population with obesity(2022)
Authors: Sanae Makhout, Eline Vermeiren, Luc Bruyndonckx, Benedicte De Winter, Stijn Verhulst
- Profiling of proteases as potential therapeutic targets(2022)
Authors: Michelle De bruyn, Ingrid De Meester, Benedicte De Winter
Number of pages: 259
Patents
1 - 9 of 9
- Method for determining the severity and prognosis of rsv infection (Inventor)
- Mucins and isoforms thereof in diseases characterized by barrier dysfunction (Inventor)
- Mucin isoforms in diseases characterized by barrier dysfunction (Inventor)
- Mucins and isoforms thereof in diseases characterized by barrier dysfunction (Inventor)
- Method for determining the severity and prognosis of RSV infection (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Mucin isoforms in diseases characterized by barrier dysfunction (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
Linked dataset
1 - 1 of 1